Approximately thirty percent of the 926 recipients of Bharat Biotech’s Covaxin suffered adverse events of special interest (AESI), according to a recent study by experts at Banaras Hindu University (BHU).
One percent of participants had Guillain-Barre syndrome, which causes weakness in the arms and legs due to nerve damage, and stroke, according to the adverse events recorded by the recipients.
The adult participants had a range of problems, such as nervous system illnesses, musculoskeletal disorders, and general disorders.
Skin and subcutaneous problems, general disorders, and nervous system illnesses were the most common AESIs among teenagers. Furthermore, the study found that about 4.6% of women had irregular menstruation.
According to the study, around one-third of the participants had AESIs. The three most frequent conditions seen in teenagers following vaccination were general diseases, nervous system disorders, and new-onset skin and subcutaneous illnesses.”
According to the research, four adult deaths—three of them female and one of them male—were documented, as PTI reported. It said that all four had diabetes, three had hypertension, and two had a history of COVID-19 prior to immunization.
“Adults receiving three doses and those receiving one dose of BBV152 were respectively at four and two times higher risk of AESIs compared with adults receiving two doses of the Covaxin,” according to the research.
The research was carried out between January 2022 and August 2023. According to the study, around half of the sample size reported having an infection, with viral upper respiratory tract infections being the most prevalent kind.
When contacted for comment, Bharat Biotech stated that company has an outstanding safety record and that several studies on the safety of Covaxin have been conducted and published in peer-reviewed publications. It also listed a number of prerequisites for this kind of research, one of which was an evaluation of the participants’ AESI profiles.
It further said that over the course of the investigation, the safety profiles of the unvaccinated participants should be compared. The Covaxin research was conducted just a few days after AstraZeneca pulled the Covid-19 vaccine, which was sold as “Covishield” in India, due to unusual adverse effects such blood clotting.
-Raja Aditya
